rNPV (Risk-Adjusted Net Present Value)
The net present value of a drug programme’s cash flows after each year’s flow has been weighted by the probability that the programme reaches that point. The standard valuation for a development-stage biotech, applied programme by programme and summed. The gap between a programme’s unrisked NPV and its rNPV is the value that is still probability, which is why a trial readout moves a share price more than any change in the discount rate.
Where rNPV (Risk-Adjusted Net Present Value) comes up
See it built in a working model
- Biotech rNPV and sum-of-the-parts model Three programmes, stage probabilities, launch curves, SOTP.
- Pharma royalty and licensing model Tiered royalties, milestones, probability, purchase IRR.
Keep reading
Healthcare financial modelsRelated Healthcare terms
Go further than reading
The written material is free. These are the ways to get it applied to your own work.
CV Review by a Human
Written margin-note feedback on structure, impact bullets and ATS-readability. Reviewed by Suro, not an AI score.
US$25 48h turnaround
Cover Letter Review by a Human
Line-by-line review of argument, tailoring and tone, with a rewritten opening as a worked example.
US$50 48h turnaround
L3VLUP Pro
The subscription: personalised alerts, Apply Packs, every answer marked, full history and the whole research library.
US$25 /month
Browse the full glossary: 416 finance recruiting and technical terms, in plain English.